Blueprint Medicines Corp (BPMC)
104.92
-1.72
(-1.61%)
USD |
NASDAQ |
May 17, 16:00
104.92
0.00 (0.00%)
After-Hours: 20:00
Blueprint Medicines Free Cash Flow: -429.98M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -429.98M |
| December 31, 2023 | -452.91M |
| September 30, 2023 | -492.19M |
| June 30, 2023 | -515.08M |
| March 31, 2023 | -502.86M |
| December 31, 2022 | -511.20M |
| September 30, 2022 | -661.83M |
| June 30, 2022 | -624.81M |
| March 31, 2022 | -567.82M |
| December 31, 2021 | -559.89M |
| September 30, 2021 | -311.86M |
| June 30, 2021 | 407.06M |
| March 31, 2021 | 368.78M |
| December 31, 2020 | 383.88M |
| September 30, 2020 | 360.58M |
| June 30, 2020 | -339.63M |
| March 31, 2020 | -320.92M |
| December 31, 2019 | -292.03M |
| September 30, 2019 | -311.25M |
| Date | Value |
|---|---|
| June 30, 2019 | -290.99M |
| March 31, 2019 | -213.77M |
| December 31, 2018 | -187.69M |
| September 30, 2018 | -165.01M |
| June 30, 2018 | -138.38M |
| March 31, 2018 | -159.96M |
| December 31, 2017 | -135.38M |
| September 30, 2017 | -108.86M |
| June 30, 2017 | -97.02M |
| March 31, 2017 | -87.65M |
| December 31, 2016 | -26.87M |
| September 30, 2016 | -24.85M |
| June 30, 2016 | -18.98M |
| March 31, 2016 | -11.94M |
| December 31, 2015 | -36.56M |
| September 30, 2015 | -31.74M |
| June 30, 2015 | -27.21M |
| March 31, 2015 | -24.52M |
| December 31, 2014 | -36.10M |
Free Cash Flow Range, Past 5 Years
-661.83M
Minimum
Sep 2022
407.06M
Maximum
Jun 2021
-283.25M
Average
-384.81M
Median
Free Cash Flow Benchmarks
| Ligand Pharmaceuticals Inc | -19.62M |
| Apellis Pharmaceuticals Inc | -550.90M |
| Alnylam Pharmaceuticals Inc | 127.82M |
| Biomarin Pharmaceutical Inc | 163.21M |
| Corcept Therapeutics Inc | 124.84M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -101.51M |
| Cash from Investing (Quarterly) | 77.13M |
| Cash from Financing (Quarterly) | 66.96M |
| Free Cash Flow Per Share (Quarterly) | -1.608 |
| Free Cash Flow to Equity (Quarterly) | -103.19M |
| Free Cash Flow to Firm (Quarterly) | -96.73M |
| Free Cash Flow Yield | -6.67% |